Sitemap
Omry Sendik

Omry Sendik

2 min readSep 30, 2025

๐—ง๐—ต๐—ฒ ๐—œ๐—ป๐˜€๐˜‚๐—ฟ๐˜๐—ฒ๐—ฐ๐—ต ๐—™๐—น๐˜†๐˜„๐—ต๐—ฒ๐—ฒ๐—น ๐—œ๐˜€ ๐—ง๐˜‚๐—ฟ๐—ป๐—ถ๐—ป๐—ด ๐—”๐—ด๐—ฎ๐—ถ๐—ป

After a bruising couple of years, the signal in the noise is getting clear: capital is returning, more selectively, and operators are prioritizing underwriting discipline over blitz-scale. Thatโ€™s healthy.
In H1โ€™25, insurtech investment reached ~$2.6B across 244 deals, putting the year on track to modestly surpass 2024.
[๐˜ด๐˜ฆ๐˜ฆ ๐˜ญ๐˜ช๐˜ฏ๐˜ฌ #1]

At the same time, funding mix is shifting and pacing remains measured (Gallagher Re shows Q2โ€™25 down QoQ to ~$1.09B with P&C at a multi-year low), which underscores the new bar: profitable growth with credible loss performance.
[๐˜ด๐˜ฆ๐˜ฆ ๐˜ญ๐˜ช๐˜ฏ๐˜ฌ #2]

Whatโ€™s most encouraging is that several public insurtechs are now reporting quarterly results that reflect this mindset:

Lemonade (Q2โ€™25): In-force premium hit $1.08B (+29% YoY) and revenue grew +35%. Gross loss ratio was 67% in the quarter, with TTM GLR at 70%, now finally inside their target range.
In laymanโ€™s terms, this means growth, while improving loss costs. ๐—ข๐—ฟ ๐—ถ๐—ป ๐—บ๐˜† ๐˜„๐—ผ๐—ฟ๐—ฑ๐˜€, ๐˜๐—ต๐—ฒ ๐—ถ๐—ป๐—ฑ๐˜‚๐˜€๐˜๐—ฟ๐˜† ๐—ถ๐˜€ ๐—น๐—ฒ๐—ฎ๐—ฟ๐—ป๐—ถ๐—ป๐—ด ๐˜๐—ต๐—ฎ๐˜ ๐—ถ๐˜ ๐—ฐ๐—ฎ๐—ปโ€™๐˜ ๐—ฎ๐—ฐ๐—ฐ๐—ฒ๐—ฝ๐˜ ๐—ด๐—ฟ๐—ผ๐˜„๐˜๐—ต ๐—ฎ๐˜ ๐—ฎ๐—น๐—น ๐˜๐—ฒ๐—ฟ๐—บ๐˜€. ๐—Ÿ๐—ผ๐˜€๐˜€ ๐—ฟ๐—ฎ๐˜๐—ถ๐—ผ๐˜€ ๐—บ๐—ฎ๐˜๐˜๐—ฒ๐—ฟ.

Root (Q2โ€™25): Posted a 95.2 combined ratio (-7.5 pts YoY) and highlighted a ~60% gross accident-period loss ratio, alongside +21% YoY growth in GEP (Gross Earned Premiums).
๐—ง๐—ต๐—ถ๐˜€ ๐—ถ๐˜€ ๐˜„๐—ต๐—ฎ๐˜ ๐—œ ๐—ฐ๐—ฎ๐—น๐—น ๐—ต๐—ฒ๐—ฎ๐—น๐˜๐—ต๐˜† ๐—ด๐—ฟ๐—ผ๐˜„๐˜๐—ต.

Get Omry Sendikโ€™s stories inย yourย inbox

Join Medium for free to get updates fromย thisย writer.

Hippo (Q2โ€™25): Consolidated net loss ratio 47%, a jaw dropping 46-point YoY improvement, with revenue up 31% to $117M.

Oscar Health (Q2โ€™25): A different line of business, but instructive: Loss Ratio 91.1% amid tougher individual-market morbidity and risk-adjustment dynamics. Full-year LR was higher.

Why this matters:
โ€ข The market is rewarding teams that treat โ€œgrowthโ€ as an output of sound underwriting.
โ€ข Investors are still writing checks, but theyโ€™re asking for loss-run credibility, clear rate-adequacy narratives, and operating cadence (filings, reserving, claims cycle times) that compare with best-in-class carriers.
โ€ข The public sources (below) show that when loss ratios are where they should be, cost of capital follows.

What great business looks like in 2025:
1. Report loss ratios (and components) every quarter, with what drives it.
2. Grow where unit economics are proven.
3. Use AI for real risk work (triage, fraud, FNOL to subrogation), not theater.

๐—œ๐—ป๐˜€๐˜‚๐—ฟ๐˜๐—ฒ๐—ฐ๐—ต ๐—ถ๐˜€๐—ปโ€™๐˜ โ€œ๐—ฏ๐—ฎ๐—ฐ๐—ธโ€ ๐—ฏ๐—ฒ๐—ฐ๐—ฎ๐˜‚๐˜€๐—ฒ ๐˜ƒ๐—ฎ๐—น๐˜‚๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐˜€ ๐˜€๐—ฎ๐˜† ๐˜€๐—ผ. ๐—œ๐˜โ€™๐˜€ ๐—ฏ๐—ฎ๐—ฐ๐—ธ ๐—ฏ๐—ฒ๐—ฐ๐—ฎ๐˜‚๐˜€๐—ฒ ๐˜‚๐—ป๐—ฑ๐—ฒ๐—ฟ๐˜„๐—ฟ๐—ถ๐˜๐—ถ๐—ป๐—ด ๐—ถ๐˜€. ๐—ž๐—ฒ๐—ฒ๐—ฝ ๐˜๐—ต๐—ฒ ๐—ฟ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜๐˜€ ๐—ต๐—ผ๐—ป๐—ฒ๐˜€๐˜, ๐—ฝ๐˜‚๐—ฏ๐—น๐—ถ๐˜€๐—ต ๐˜†๐—ผ๐˜‚๐—ฟ ๐—น๐—ผ๐˜€๐˜€ ๐—ฟ๐˜‚๐—ป๐˜€, ๐—ฎ๐—ป๐—ฑ ๐—น๐—ฒ๐˜ ๐˜๐—ต๐—ฒ ๐—ฐ๐—ผ๐—บ๐—ฝ๐—ผ๐˜‚๐—ป๐—ฑ๐—ถ๐—ป๐—ด ๐—ฑ๐—ผ ๐˜๐—ต๐—ฒ ๐˜๐—ฎ๐—น๐—ธ๐—ถ๐—ป๐—ด.

Sources:
1. https://lnkd.in/dZw_zfys
2. https://lnkd.in/d4h9VV7z